Harrow Inc (HROW)

Apr 01, 2025

Where Harrow Stands With Analysts - Benzinga

Apr 01, 2025

Apr 01, 2025

B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating - MarketScreener

Apr 01, 2025

Mar 29, 2025

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives By GuruFocus - Investing.com Canada

Mar 29, 2025

Mar 29, 2025

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Mar 29, 2025

Mar 29, 2025

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Mar 29, 2025

Mar 28, 2025

Harrow Health Reports Strong 2024 Financial Performance - TipRanks

Mar 28, 2025

Mar 28, 2025

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha

Mar 28, 2025

Mar 27, 2025

Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Mar 27, 2025

Mar 27, 2025

Harrow: Q4 Earnings Snapshot - The Advocate

Mar 27, 2025

Mar 27, 2025

Harrow Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Joplin Globe

Mar 27, 2025

Mar 27, 2025

Harrow Sets Stage for Major 2024 Financial Review: Q4 and Annual Results Coming March 27 - Stock Titan

Mar 27, 2025

Mar 26, 2025

Harrow Inc. sees $150k stock sale by Opaleye Management - Investing.com

Mar 26, 2025

Mar 24, 2025

Harrow sees shares increase following drug approval - Nashville Post

Mar 24, 2025

Mar 24, 2025

Craig-Hallum Reaffirms Their Buy Rating on Harrow Health (HROW) - The Globe and Mail

Mar 24, 2025

Mar 24, 2025

CMS approves separate reimbursement for Harrow’s TRIESENCE - Investing.com

Mar 24, 2025

Mar 24, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire

Mar 24, 2025

Mar 24, 2025

TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan

Mar 24, 2025

Mar 22, 2025

Harrow Inc (HROW) Shares Up 1.14% on Mar 22 - GuruFocus

Mar 22, 2025

Mar 22, 2025

Opaleye management sells $148,200 in Harrow, Inc. stock - Investing.com India

Mar 22, 2025

Mar 21, 2025

What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus

Mar 21, 2025

Mar 21, 2025

Opaleye Management Inc. Adjusts Stake in Harrow Inc. - GuruFocus

Mar 21, 2025

Mar 21, 2025

Bank of New York Mellon Corp Has $2.90 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World

Mar 21, 2025

Mar 21, 2025

Harrow Inc (HROW) Shares Up 2.97% on Mar 21 - GuruFocus

Mar 21, 2025

Mar 20, 2025

Opaleye management sells $148,200 in Harrow, Inc. stock By Investing.com - Investing.com South Africa

Mar 20, 2025

Mar 19, 2025

Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha

Mar 19, 2025

Mar 19, 2025

H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 19, 2025

H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target - Investing.com India

Mar 19, 2025

Mar 19, 2025

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial - GlobeNewswire Inc.

Mar 19, 2025

Mar 18, 2025

Harrow stock surges on preliminary Q4 numbers - Nashville Post

Mar 18, 2025

Mar 18, 2025

Sector Update: Health Care -March 18, 2025 at 08:49 am EDT - Marketscreener.com

Mar 18, 2025

Mar 18, 2025

Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews

Mar 18, 2025

Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga India

Mar 18, 2025

Mar 18, 2025

Harrow Reports Preliminary 2024 Q4 and Full-Year Financial Results, Provides 2025 Guidance and Launches New Initiative - VisionMonday.com

Mar 18, 2025

Mar 17, 2025

Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus.com

Mar 17, 2025

Mar 17, 2025

Harrow Completes Transfer of the TRIESENCE® New Drug Application - Business Wire

Mar 17, 2025

Mar 17, 2025

Harrow Reports Q4 Preliminary Revenue -- Shares Rise After Hours -March 17, 2025 at 04:30 pm EDT - Marketscreener.com

Mar 17, 2025

Mar 17, 2025

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance - Business Wire

Mar 17, 2025

Mar 17, 2025

Harrow Launches VEVYE® Access for All - Business Wire

Mar 17, 2025

Mar 17, 2025

Harrow Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga

Mar 17, 2025

Mar 15, 2025

HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 15, 2025

Mar 11, 2025

Harrow shares react modestly to FDA move | Area Stocks - Nashville Post

Mar 11, 2025

Mar 11, 2025

Harrow shares react modestly to FDA move - Nashville Post

Mar 11, 2025

Mar 11, 2025

Harrow shares react to FDA move - Nashville Post

Mar 11, 2025

Mar 11, 2025

Harrow Signs 5-Year Supply Deal for Triesence -March 11, 2025 at 08:36 am EDT - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Harrow Executes Five-Year Strategic Supply And Development Agreement For TRIESENCE - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® - Business Wire

Mar 11, 2025